Suven Life sciences is a company that I am tracking from 2014 This is what I wrote in 2014 on their optionality
But as you would have seen expecting the company to not to commercialize any R&D work for 18 years would be a real surprise
In 2015, I noted the possibility of monetizing their lead molecule in 2017
SUVN 502. For this molecule, we completed Phase-Ib trials and commenced preparations for the Phase-IIa (POC) trial. We hope to initiate patient trials during the second half of the current year and are hopeful of monetising this molecule post successful completion of the study in fiscal 2017
But few years with the company and I understood that
Drug discovery is a long, hard and uncertain process and putting your odds is as good as throwing a dice. There are far few too many variables to model an outcome
However we also observed that the company is building a different and more sustainable game plan
For a company earning 12-15% ROE and growing at 10-15%, this seems to be fair or even above par, however, we need to be cognizant that Suven is building various verticals that are yet not contributing … Read the rest